AB1143 The impact of anti-cyclic citrullinated peptide seropositivity on erosion prevalence among patients with rheumatoid arthritis of varying disease duration
Leslie R. Harrold(University of Massachusetts Chan Medical School), Joel M. Kremer(Research Foundation for the State University of New York), Seán Connolly(Bristol-Myers Squibb (Sweden)), Sabrina Rebello(Amyloidosis Foundation), Karen Price(Purchase College), Heather J. Litman(Thermo Fisher Scientific (United States)), E. Alemao(Bristol-Myers Squibb (Sweden))
Cited by 2
Related Papers
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183